State Street SPDR S&P Biotech ETF
745 hedge funds and large institutions have $8.02B invested in State Street SPDR S&P Biotech ETF in 2023 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 171 increasing their positions, 271 reducing their positions, and 67 closing their positions.
113% more first-time investments, than exits
New positions opened: 143 | Existing positions closed: 67
35% more funds holding in top 10
Funds holding in top 10: 17 → 23 (+6)
21% more capital invested
Capital invested by funds: $6.63B → $8.02B (+$1.39B)
10% more funds holding
Funds holding: 679 → 745 (+66)
7.05% less ownership
Funds ownership: 117.52% → 110.47% (-7%)
37% less repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 271
38% less call options, than puts
Call options by funds: $2.01B | Put options by funds: $3.26B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$330M |
| 2 |
Morgan Stanley
New York
|
+$251M |
| 3 |
CHP
Castle Hook Partners
New York
|
+$134M |
| 4 |
MCM
Moore Capital Management
New York
|
+$129M |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$101M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$344M |
| 2 |
Goldman Sachs
New York
|
-$198M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$164M |
| 4 |
Citigroup
New York
|
-$112M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$63.9M |
XBI Hedge Fund Activity: Q4 2023 in Review
745 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2023, worth a combined $8.02B — up 21% from $6.63B a quarter earlier.
Buyers outnumbered sellers: 143 funds opened new XBI positions and 67 closed out — a net gain of 76 holders — while 171 added to existing stakes and 271 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $330M. The largest seller was Bank of America, cutting an estimated $344M.
- 745 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2023, up from 679 in Q3 2023.
- Funds reported $8.02B of State Street SPDR S&P Biotech ETF stock for Q4 2023, up 21% quarter-over-quarter.
- 143 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2023 and 67 closed out, a net change of +76 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2023 was Avoro Capital Advisors, an estimated $330M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2023 was Bank of America, an estimated $344M sold.
Based on aggregated 13F filings for Q4 2023.